WithdrawnPhase 1NCT03776695
Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in ZIKV Infected Patients
Studying Zika virus disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tychan Pte Ltd.
- Principal Investigator
- Jenny Low, MBBSSingapore General Hospital
- Intervention
- Tyzivumab(biological)
- Eligibility
- 21-60 years · All sexes
- Timeline
- 2018 – 2022
Study locations (1)
- SingHealth Investigational Medicine Unit, Singapore, Singapore
Collaborators
Singapore Clinical Research Institute · Duke-NUS Graduate Medical School
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03776695 on ClinicalTrials.govOther trials for Zika virus disease
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT04398901Neurodevelopmental Outcomes in ZIKV-Exposed ChildrenChildren's National Research Institute
- ACTIVE NOT RECRUITINGPHASE3NCT03037164INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted InfectionsCerus Corporation
- RECRUITINGNCT01386424Screening for LID Clinical Studies Unit Healthy Volunteer ProtocolsNational Institute of Allergy and Infectious Diseases (NIAID)